<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl0005">
 <label>Table 1</label>
 <caption>
  <p>Summary of clinical studies investigating proposed treatments of COVID-19.</p>
 </caption>
 <alt-text id="at0015">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th colspan="2" align="left">Investigation</th>
    <th align="left">Study</th>
    <th align="left">Country</th>
    <th align="left">Study type</th>
    <th align="left">Population (n patients)</th>
    <th align="left">Intervention group</th>
    <th align="left">Control group</th>
    <th align="left">Outcome</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" valign="middle" rowspan="8">Anti-viral therapies</td>
    <td align="left" valign="middle" rowspan="2">LPV/ RTV</td>
    <td align="left">Cao, B. et al. [
     <xref rid="bib0185" ref-type="bibr">37</xref>]
    </td>
    <td align="left">China</td>
    <td align="left">Open-label, randomized,controlled trial</td>
    <td align="left">&gt;18 years, severe COVID-19 pneumonia cases. (n = 199)</td>
    <td align="left">LPV/ RTV (400 mg/100 mg) orally b.i.d. plus standard care for 14 days.</td>
    <td align="left">Standard care only for 14 days.</td>
    <td align="left">No benefit was observed with LPV/ RTV beyond standard care treatment.</td>
   </tr>
   <tr>
    <td align="left">Deng, L. et al. [
     <xref rid="bib0200" ref-type="bibr">40</xref>]
    </td>
    <td align="left">China</td>
    <td align="left">Retrospective cohort study</td>
    <td align="left">≥18years, confirmed COVID-19 cases, without Invasive ventilation. (n = 33)</td>
    <td align="left">Umifenovir (Arbidol®) (200 mg/ 8 h) plus LPV/ RTV (400 mg/100 mg) for 5–21 days.</td>
    <td align="left">Oral LPV/ RTV only for 5–21 days.</td>
    <td align="left">Better clinical, radiological and laboratorial (RT-PCR negativity) response was observed in the (Umifenovir + lPV/ RTV) group.</td>
   </tr>
   <tr>
    <td align="left">Remdesivir</td>
    <td align="left">Grein, J. et al. [
     <xref rid="bib0180" ref-type="bibr">36</xref>]
    </td>
    <td align="left">Multi-national</td>
    <td align="left">Cohort study.</td>
    <td align="left">Hospitalized confirmed COVID-19 cases with O
     <sub>2</sub> saturation ≤ 94% or receiving O
     <sub>2</sub> support. (n = 61)
    </td>
    <td align="left">Remdesivir (200 mg IV. On D1 then 100 mg daily) total duration: 10 days.</td>
    <td align="left">NA</td>
    <td align="left">Clinical improvement was observed in 68 % of patients. Total mortality rate was 13 %.</td>
   </tr>
   <tr>
    <td align="left" valign="middle" rowspan="5">CQ/HCQ</td>
    <td align="left">Chen, J. et al. [
     <xref rid="bib0295" ref-type="bibr">59</xref>]
    </td>
    <td align="left">China</td>
    <td align="left">Randomized pilot study</td>
    <td align="left">Hospitalized confirmed COVID-19 cases. (n = 30)</td>
    <td align="left">HCQ (400 mg / day) for 5 days plus conventional treatments.</td>
    <td align="left">Conventional treatment only.</td>
    <td align="left">Duration from hospitalization to COVID-19 nucleic acid negativity, clinical improvement, and radiological changes were comparable with the control group.</td>
   </tr>
   <tr>
    <td align="left">Chen, Z. et al.
     <xref rid="tblfn0020" ref-type="table-fn">d</xref> [
     <xref rid="bib0315" ref-type="bibr">63</xref>]
    </td>
    <td align="left">China</td>
    <td align="left">Randomized clinical trial</td>
    <td align="left">≥ 18 years, COVID-19 pneumonia cases. (n = 62)</td>
    <td align="left">HCQ (400 mg/day) orally for 5-days.</td>
    <td align="left">Standard treatment only.</td>
    <td align="left">HCQ significantly shortened TTCR and promote the absorption of pneumonia.</td>
   </tr>
   <tr>
    <td align="left" valign="middle" rowspan="2">Gautret, P. et al. [
     <xref rid="bib0320" ref-type="bibr">64</xref>]
    </td>
    <td align="left" valign="middle" rowspan="2">France</td>
    <td align="left" valign="middle" rowspan="2">open-label Non-randomized clinical trial</td>
    <td align="left" valign="middle" rowspan="2">&gt;12 years, hospitalized confirmed COVID-19 cases. (n = 36)</td>
    <td align="left">HCQ sulfate orally (200 mg t.i.d./day) for ten days</td>
    <td align="left" valign="middle" rowspan="2">Standard treatment only.</td>
    <td align="left" valign="middle" rowspan="2">HCQ was significantly associated with viral load reduction/disappearance in COVID-19 patients and azithromycin reinforced its effect.</td>
   </tr>
   <tr>
    <td align="left">-Six patients received Azithromycin (500 mg) on D1 followed by (250 mg /day) the next four days.</td>
   </tr>
   <tr>
    <td align="left">Gautret, P. et al.
     <xref rid="tblfn0020" ref-type="table-fn">d</xref> [
     <xref rid="bib0325" ref-type="bibr">65</xref>]
    </td>
    <td align="left">France</td>
    <td align="left">Observational study</td>
    <td align="left">Hospitalized confirmed COVID-19 cases (n = 80)</td>
    <td align="left">HCQ sulfate orally (200 mg t.i.d./day) for ten days plus Azithromycin (500 mg on D1 followed by 250 mg/ day) for the next four days.</td>
    <td align="left">NA</td>
    <td align="left">Rapid fall of viral load (93 % negative PCR at D8). Virus cultures from respiratory samples were negative in 97.5 % patients at D5.</td>
   </tr>
   <tr>
    <td align="left">Anti-viral therapies</td>
    <td align="left">CQ/HCQ</td>
    <td align="left">Tang, W. et al.
     <xref rid="tblfn0020" ref-type="table-fn">d</xref> [
     <xref rid="bib0300" ref-type="bibr">60</xref>]
    </td>
    <td align="left">China</td>
    <td align="left">Open-label, randomized, controlled trial.</td>
    <td align="left">≥ 18 years, Hospitalized confirmed COVID-19 cases. (n = 150)</td>
    <td align="left">HCQ (1200 mg/day for 3 days, then 800 mg/day) total duration: 2−3 weeks for mild/moderate or severe patients, respectively.</td>
    <td align="left">Standard treatment only.</td>
    <td align="left">HCQ did not result in a higher negative conversion rate, but more clinical improvement than the control group was observed.</td>
   </tr>
   <tr>
    <td align="left" valign="middle" rowspan="2">Adjunctive Therapy</td>
    <td align="left" valign="middle" rowspan="2">Tocilizumab</td>
    <td align="left" valign="middle" rowspan="2">Xu, X. et al. [
     <xref rid="bib0410" ref-type="bibr">82</xref>]
    </td>
    <td align="left" valign="middle" rowspan="2">China</td>
    <td align="left" valign="middle" rowspan="2">Observation study</td>
    <td align="left">Severe or critical COVID-19 patients</td>
    <td align="left">Tocilizumab IV. (400 mg once)
     <xref rid="tblfn0005" ref-type="table-fn">a</xref>
    </td>
    <td align="left" valign="middle" rowspan="2">NA</td>
    <td align="left" valign="middle" rowspan="2">All patients had clinical, radiological and laboratory (LYM and CRP level) improvement.</td>
   </tr>
   <tr>
    <td align="left">(n = 21)</td>
    <td align="left">Three patients had another 400 mg within 12 h.</td>
   </tr>
   <tr>
    <td align="left"/>
    <td align="left">Siltuximab</td>
    <td align="left">Gritti, G. et al.
     <xref rid="tblfn0020" ref-type="table-fn">d</xref> [
     <xref rid="bib0455" ref-type="bibr">91</xref>]
    </td>
    <td align="left">Italy</td>
    <td align="left">Retrospective study</td>
    <td align="left">Confirmed COVID-19 pneumonia cases with ARDS. (n = 21)</td>
    <td align="left">Siltuximab IV. (11 mg /kg /day) over 1 h plus standard treatment.</td>
    <td align="left">NA</td>
    <td align="left">Potential role in improving the clinical condition (33 % of patients improved, and 43 % stabilized, while 24 % had worsening in condition.</td>
   </tr>
   <tr>
    <td align="left" valign="middle" rowspan="2"/>
    <td align="left" valign="middle" rowspan="2">convalescent plasma</td>
    <td align="left" valign="middle" rowspan="2">Shen, C. et al. [
     <xref rid="bib0405" ref-type="bibr">81</xref>]
    </td>
    <td align="left" valign="middle" rowspan="2">China</td>
    <td align="left" valign="middle" rowspan="2">Case series</td>
    <td align="left" valign="middle" rowspan="2">Confirmed critically ill COVID-19 cases on mechanical ventilation. with (n = 5)</td>
    <td align="left" valign="middle" rowspan="2">Convalescent plasma (400 mL) with a SARS-CoV-2 specific antibody (IgG).
     <xref rid="tblfn0010" ref-type="table-fn">b</xref>
    </td>
    <td align="left" valign="middle" rowspan="2">NA</td>
    <td align="left">Clinical improvement was reported in all patients.</td>
   </tr>
   <tr>
    <td align="left">Viral loads became negative within 12 days after transfusion.</td>
   </tr>
   <tr>
    <td align="left"/>
    <td align="left">CS + IVIG</td>
    <td align="left">Zhou, Zhi-Guo. et al.
     <xref rid="tblfn0020" ref-type="table-fn">d</xref> [
     <xref rid="bib0390" ref-type="bibr">78</xref>]
    </td>
    <td align="left">China</td>
    <td align="left">Retrospective study</td>
    <td align="left">Patients who failed to respond to low-dose CS (40−80 mg/day) and IVIG (10 g/day). (n = 3)</td>
    <td align="left">CS (160 mg/day) plus IVIG (20 g/d).
     <xref rid="tblfn0015" ref-type="table-fn">c</xref>
    </td>
    <td align="left">NA</td>
    <td align="left">Moderate dose of CS + IVIG reversed the continued deterioration of COVID-19 patients who failed to respond to the low-dose therapy.</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>Abbreviations: 
    <bold>n</bold>: number, 
    <bold>LPV/ RTV</bold>: Lopinavir/Ritonavir, 
    <bold>b.i.d.</bold>: Twice daily, 
    <bold>h</bold>: Hour, 
    <bold>O
     <sub>2</sub>:
    </bold> oxygen, 
    <bold>CQ /HCQ</bold>: Hydroxychloroquine, 
    <bold>TTCR</bold>: Time to clinical recovery, 
    <bold>D</bold>: Day, 
    <bold>PCR</bold>: Polymerase chain reaction, 
    <bold>IV</bold>: Intravenous, 
    <bold>LYM</bold>: Lymphocytes, 
    <bold>CRP</bold>: C-reactive protein, 
    <bold>CS</bold>: Corticosteroids, 
    <bold>IVIG:</bold> Intravenous Immunoglobulins.
   </p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tblfn0005">
   <label>a</label>
   <p id="npar0005">Patients also received standard care including Lopinavir, methylprednisolone, and oxygen therapy.</p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tblfn0010">
   <label>b</label>
   <p id="npar0010">All patients received antiviral agents and methylprednisolone.</p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tblfn0015">
   <label>c</label>
   <p id="npar0015">Patients also received, as required, oxygen therapy, antiviral treatment, antibiotic treatment, extracorporeal membrane oxygenation (ECMO), and continuous renal replacement therapy (CRRT).</p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tblfn0020">
   <label>d</label>
   <p id="npar0020">Pre-print.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
